How long does 25N-NBOMe last?

The total duration of 25N-NBOMe via sublingual is 5 hours to 10 hours. Onset typically occurs within 45 minutes to 1.3 hours. Peak effects last 2 hours to 3 hours.

25N-NBOMe — SubstanceWiki

25N-NBOMe (the N-nitro substituted NBOMe compound) is a rare and exceptionally poorly characterized member of the NBOMe series. Unlike the major NBOMe compounds (25I-, 25B-, 25C-NBOMe), which carry halogen substituents at the 4-position, 25N-NBOMe carries a nitro (NO2) group — an electron-withdrawing substitution that alters the electronic character of the phenyl ring and may substantially change receptor binding properties. Formal pharmacological data are extremely scarce.

Based on available structure-activity relationships for the 2C family and NBOMe series, 25N-NBOMe is presumed to act as a 5-HT2A agonist. However, the nitro substitution is associated with reduced potency compared to halogenated analogs in the 2C series (2C-N, the parent compound, is less potent than 2C-I or 2C-B). Whether the NBOMe modification rescues or amplifies potency to a similar degree as with halogenated analogs is not established by published pharmacological data.

Community reports of 25N-NBOMe use are rare, and any recreational use of this compound carries extraordinary risk given the near-total absence of human safety data. The general hazards of NBOMe compounds — potency at microgram doses, vasoconstriction, steep dose-response curve, seizure potential — must be assumed until demonstrated otherwise by formal study.

How It Feels

The onset takes shape over twenty to thirty minutes as a moderate bitter numbness in the mouth gradually gives way to a building body awareness. A stimulant undercurrent begins to hum through the nervous system -- mild but distinct, raising the heart rate and lending a slight restless energy to the limbs. The vasoconstriction typical of the NBOMe class is present but moderate, producing a mild coolness in the fingers and a subtle tightening in the chest that most users find manageable. The first visual changes appear as a gentle intensification of color and an increased awareness of textural detail.

Over the next hour, the experience develops into a state of moderate psychedelic alteration. Visual geometry emerges in soft, flowing patterns that overlay surfaces with moderate density. The patterns are less aggressive and less brilliantly colored than those produced by 25I-NBOMe or 25B-NBOMe -- they tend toward warmer tones and more organic shapes, shifting at a leisurely pace rather than the frantic cycling of the more potent NBOMe compounds. Colors are enhanced and slightly shifted but retain a naturalistic quality. There is a pleasant dreamlike softness to the visual alterations, as though reality has been lightly blurred at the edges while remaining sharp at the center of attention.

The headspace at the peak is mild and clear. Thoughts flow with a gentle fluidity, and there is a quiet emotional warmth that makes the experience pleasant without being overwhelming. Introspection is possible but not compelled -- the substance does not push the mind in any particular direction. Music is moderately enhanced, and social interaction feels comfortable and natural. The body load remains manageable throughout, with mild jaw tension and stimulant energy being the primary physical signatures. The overall intensity sits well below the more powerful members of the NBOMe family, making this compound feel like a gentler exploration of the same pharmacological territory.

Effects begin to wane around four to five hours after onset, with visuals fading gradually and the stimulant edge softening into calm. Total duration spans five to seven hours. The comedown is unremarkable, and the aftermath is relatively clean -- some residual fatigue and perhaps a mild headache, but nothing approaching the physical toll of the more potent NBOMe compounds. The experience reads as a footnote in the series rather than a headline, offering moderate rewards at moderate cost.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(17)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Runny nose— Excessive nasal discharge commonly occurring during opioid withdrawal or from nasal irritation cause...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(8)

Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
Symmetrical texture repetition

Detection Methods

Urine Detection

25N-NBOMe is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOMe compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.

Blood and Serum Detection

Blood detection windows for 25N-NBOMe are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOMe compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.

Standard Drug Panel Inclusion

25N-NBOMe is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.

Confirmatory Methods

Definitive identification of 25N-NBOMe requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOMe compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.

Reagent Testing (Harm Reduction)

Reagent testing is critically important for NBOMe compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25N-NBOMe, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOMe compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOMe compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOMe compound.

Interactions

Substance	Status	Note
Cocaine	Unsafe	—
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Caffeine	Uncertain	—
Cannabis	Uncertain	—
MDMA	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 63 key interactions out of 84 total.

Toxicity & Safety

Essentially Unknown Toxicity Profile

The toxicity of 25N-NBOMe is essentially unknown due to the near-total absence of human data. No confirmed fatalities specifically attributed to 25N-NBOMe have been documented in available literature. This likely reflects extreme rarity rather than safety.

Assumed Class Hazards

By structural membership in the NBOMe series, the following hazards are assumed until demonstrated otherwise:

Vasoconstriction via alpha-adrenergic receptor activation
Tachycardia and hypertension
Seizure potential at high doses
Steep dose-response curve with a narrow safety window

Drug Interactions

Identical precautions to other NBOMe compounds:

Stimulants: absolutely contraindicated
Lithium: absolutely contraindicated
MAOIs: avoid

Contraindications

Cardiovascular disease or vascular disorders
History of psychotic disorders
Concurrent stimulant or lithium use

Addiction Potential

not habit-forming

Overdose Information

fatal in some cases. Although there are no reported deaths caused by 25N-NBOMe at this time,potentially fatal at heavy dosages.

It is strongly recommended that one use harm reduction practices when using this drug.

25N-not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25N-almost immediately after ingestion. After that,37 days to be back at baseline (in the absence of further consumption). 25N-NBOMe presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of 25N-NBOMe all psychedelics will have a reduced effect.

Overdose
Austria: 25N-NBOMe is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Germany: 25N-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of June 9, 2016. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: 25N-NBOMe is a Schedule I controlled substance.
Switzerland: 25N-NBOMe is a controlled substance specifically named under Verzeichnis E.
United Kingdom: 25N-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
United States: 25N-NBOMe is unscheduled in the United States. It may be considered an analogue of 2C-N (which is a Schedule I drug under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or indus

Full	almost immediately after ingestion
Half	3 days
Zero	7 days

25N-NBOMe

Quick Dosage

Dosage

sublingual

Duration

sublingual

How It Feels

Subjective Effects

Physical Effects

Physical(17)

Tactile(1)

Cognitive & Perceptual Effects

Visual(8)

Pharmacology

Mechanism of Action

Structure-Activity Relationship and Uncertainty

Route of Administration

Pharmacokinetics

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Development

Prevalence

Legal Status

Harm Reduction

Extraordinary Caution Required

Test Your Substance

Sublingual Only

Ultra-Conservative Dosing

Emergency Preparedness

Toxicity & Safety

Essentially Unknown Toxicity Profile

Assumed Class Hazards

Drug Interactions

Contraindications

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (4)

See Also

References (4)

Frequently Asked Questions

Cognitive(15)

Multi-sensory(1)

Transpersonal(3)